Neurobo Historical Income Statement
| NRBO Stock | USD 3.37 0.07 2.03% |
Historical analysis of Neurobo Pharmaceuticals income statement accounts such as Other Operating Expenses of 18.8 M can show how well Neurobo Pharmaceuticals performed in making a profits. Evaluating Neurobo Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Neurobo Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Neurobo Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neurobo Pharmaceuticals is a good buy for the upcoming year.
Neurobo |
About Neurobo Income Statement Analysis
Neurobo Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Neurobo Pharmaceuticals shareholders. The income statement also shows Neurobo investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Neurobo Pharmaceuticals Income Statement Chart
Neurobo Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Neurobo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Neurobo Pharmaceuticals revenue and expense. Neurobo Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Neurobo Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 19th of April 2024, Other Operating Expenses is likely to grow to about 18.8 M, while Depreciation And Amortization is likely to drop 6,650. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Neurobo Pharmaceuticals. It is also known as Neurobo Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Neurobo Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Neurobo Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.At this time, Neurobo Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 19th of April 2024, Other Operating Expenses is likely to grow to about 18.8 M, while Depreciation And Amortization is likely to drop 6,650.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 48K | 20K | 3K | 2.9K | Cost Of Revenue | 72K | 28K | 7K | 6.7K |
Neurobo Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Neurobo Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurobo Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.1M | 46K | 48K | 8.1M | 7K | 6.7K | |
| Selling General Administrative | 2.7M | 7.8M | 8.8M | 8.6M | 6.7M | 6.9M | |
| Other Operating Expenses | 20.2M | 29.7M | 15.3M | 11.4M | 15.9M | 18.8M | |
| Operating Income | (20.2M) | (29.7M) | (15.3M) | (19.6M) | (15.9M) | (16.7M) | |
| Ebit | (20.2M) | (29.7M) | (15.3M) | (19.6M) | (15.9M) | (16.7M) | |
| Research Development | 17.5M | 21.9M | 6.5M | 2.8M | 9.2M | 11.8M | |
| Ebitda | (19.1M) | (29.7M) | (15.3M) | (11.5M) | (15.9M) | (16.7M) | |
| Total Operating Expenses | 20.2M | 29.7M | 15.3M | 11.4M | 15.9M | 18.8M | |
| Income Before Tax | (21.3M) | (29.7M) | (15.3M) | (14.0M) | (12.5M) | (13.1M) | |
| Total Other Income Expense Net | (1.1M) | 38K | 14K | 5.7M | 3.4M | 3.6M | |
| Net Income | (22.4M) | (29.6M) | (15.2M) | (6.1M) | (12.5M) | (13.1M) | |
| Income Tax Expense | 1.1M | (85K) | (62K) | (7.9M) | (7.1M) | (6.7M) | |
| Interest Income | 22K | 39K | 14K | 0.0 | 162K | 182.5K | |
| Net Income Applicable To Common Shares | (15.5M) | (21.3M) | (29.7M) | (15.3M) | (13.8M) | (14.4M) | |
| Net Interest Income | (22K) | 39K | 14K | (2.2M) | (2.0M) | (1.9M) | |
| Net Income From Continuing Ops | (21.3M) | (29.7M) | (15.3M) | (14.0M) | (11.8M) | (12.4M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neurobo Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neurobo Pharmaceuticals' short interest history, or implied volatility extrapolated from Neurobo Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.35) | Return On Equity (0.65) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.